Adaptation of a side‐effect questionnaire for identifying symptoms caused by bacillus Calmette‐Guerin intravesical therapy
Adaptation of a side‐effect questionnaire for identifying symptoms caused by bacillus Calmette‐Guerin intravesical therapy
Current treatment for high-grade non-muscle invasive bladder cancer utilizes bacillus Calmette-Guerin (BCG) installations into the bladder. Although effective, BCG toxicities often cause delay or instillation interruptions and this can consequently reduce the treatment efficacy. The importance of a patient questionnaire for identifying symptoms following BCG intravesical therapy, minimizing toxicities and improvements in patient compliance are recognized. However, as yet, a standard questionnaire is not available. The European Association Urology Nurses guidelines have suggested a survey; however, its terminology is potentially too complex to be used by the patients. A project with 3 phases was developed in order to identify the most user-friendly survey to be used in this population group. Phase 1: Identification and assessment of existing BCG side effects questionnaires. Phase 2: Adaptation and assessment of a BCG side-effect questionnaire. Phase 3: Testing of the adapted questionnaire. Following the review in phase 1, four questionnaires' were found and assessed using appraisal and text readability tools. Appraisal showed that the four surveys used difficult language for patients to use independently. Based on patient feedback, a BCG side-effect questionnaire was adapted to be more patient-friendly and appraised using the same tools from phase 1. The adapted questionnaire proved to be beneficial for both patients and health professionals. First, it was more easily understood by patients. Second, it enabled staff to better identify patients at risk, monitor treatment consequences and implement supportive measures. Despite the adaptations, however, patients continued to find the terminology used ambiguous.
BCG, clinical terminology, jargon, non-muscle invasive bladder cancer, side-effect questionnaire, survey
196-204
Semedo, Ana Filipa Goncalves
d5164fd7-fe20-4bd5-8802-ce3ee0405c0c
Martin, Rebecca
b086d68a-b900-401f-a5e1-896b36d7c39f
Kumar, Pardeep
f8eb9655-2add-454d-ae02-b2b435b351ca
Wagland, Richard
16a44dcc-29cd-4797-9af2-41ef87f64d08
Kinsella, Janette
a56f170b-0c7c-4976-ae1f-8e62a93eb8a2
Wiseman, Theresa
e3ff42ae-97ef-4640-af3d-40eeae830df9
November 2022
Semedo, Ana Filipa Goncalves
d5164fd7-fe20-4bd5-8802-ce3ee0405c0c
Martin, Rebecca
b086d68a-b900-401f-a5e1-896b36d7c39f
Kumar, Pardeep
f8eb9655-2add-454d-ae02-b2b435b351ca
Wagland, Richard
16a44dcc-29cd-4797-9af2-41ef87f64d08
Kinsella, Janette
a56f170b-0c7c-4976-ae1f-8e62a93eb8a2
Wiseman, Theresa
e3ff42ae-97ef-4640-af3d-40eeae830df9
Semedo, Ana Filipa Goncalves, Martin, Rebecca, Kumar, Pardeep, Wagland, Richard, Kinsella, Janette and Wiseman, Theresa
(2022)
Adaptation of a side‐effect questionnaire for identifying symptoms caused by bacillus Calmette‐Guerin intravesical therapy.
International Journal of Urological Nursing, 16 (3), .
(doi:10.1111/ijun.12311).
Abstract
Current treatment for high-grade non-muscle invasive bladder cancer utilizes bacillus Calmette-Guerin (BCG) installations into the bladder. Although effective, BCG toxicities often cause delay or instillation interruptions and this can consequently reduce the treatment efficacy. The importance of a patient questionnaire for identifying symptoms following BCG intravesical therapy, minimizing toxicities and improvements in patient compliance are recognized. However, as yet, a standard questionnaire is not available. The European Association Urology Nurses guidelines have suggested a survey; however, its terminology is potentially too complex to be used by the patients. A project with 3 phases was developed in order to identify the most user-friendly survey to be used in this population group. Phase 1: Identification and assessment of existing BCG side effects questionnaires. Phase 2: Adaptation and assessment of a BCG side-effect questionnaire. Phase 3: Testing of the adapted questionnaire. Following the review in phase 1, four questionnaires' were found and assessed using appraisal and text readability tools. Appraisal showed that the four surveys used difficult language for patients to use independently. Based on patient feedback, a BCG side-effect questionnaire was adapted to be more patient-friendly and appraised using the same tools from phase 1. The adapted questionnaire proved to be beneficial for both patients and health professionals. First, it was more easily understood by patients. Second, it enabled staff to better identify patients at risk, monitor treatment consequences and implement supportive measures. Despite the adaptations, however, patients continued to find the terminology used ambiguous.
This record has no associated files available for download.
More information
Accepted/In Press date: 21 December 2021
e-pub ahead of print date: 13 February 2022
Published date: November 2022
Additional Information:
Publisher Copyright:
© 2022 BAUN and John Wiley & Sons Ltd.
Keywords:
BCG, clinical terminology, jargon, non-muscle invasive bladder cancer, side-effect questionnaire, survey
Identifiers
Local EPrints ID: 468075
URI: http://eprints.soton.ac.uk/id/eprint/468075
ISSN: 1749-7701
PURE UUID: 54097c0b-ab60-432a-835d-9f2734581322
Catalogue record
Date deposited: 29 Jul 2022 16:47
Last modified: 17 Mar 2024 03:20
Export record
Altmetrics
Contributors
Author:
Ana Filipa Goncalves Semedo
Author:
Rebecca Martin
Author:
Pardeep Kumar
Author:
Janette Kinsella
Author:
Theresa Wiseman
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics